Neogenomics Inc is a leading provider of cancer-focused genetic testing and diagnostic services. The company specializes in developing advanced technologies that enhance the accuracy of cancer diagnosis and treatment planning. Through its comprehensive suite of laboratory services, Neogenomics aids healthcare providers by offering insights into genetic markers associated with various cancers, enabling personalized medicine approaches. In addition to its testing services, Neogenomics is dedicated to research and development, striving to improve and innovate methodologies that contribute to better patient outcomes in oncology. Read More
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company’s PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable.
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO)
fell 20.2% in the morning session after the company reported second-quarter results that included a significant cut to its full-year financial guidance, sparking a selloff.
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 10.2% year on year to $181.3 million. The company’s full-year revenue guidance of $723 million at the midpoint came in 2.9% below analysts’ estimates. Its non-GAAP profit of $0.03 per share was in line with analysts’ consensus estimates.
NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts.
But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the testing & diagnostics services industry, including NeoGenomics (NASDAQ:NEO) and its peers.
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on.
However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. (“Zeo” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. (“Zeo” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
NEW YORK CITY, NY / ACCESS Newswire / June 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp.("Zeo" or the "Company") (NASDAQ:NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confidently.
NEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ:NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ:NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
